C. Arianne Buchan

C. Arianne Buchan

Auto-generated profile, based on publicly available information

C. Arianne Buchan

Department of Medicine, The Ottawa Hospital

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
ABAdrian J. M. Bailey
Adrian J. M. Bailey
AKAidan M. Kirkham
Aidan M. Kirkham
MMMadeline Monaghan
Madeline Monaghan
RSRisa Shorr
Risa Shorr
CBC. Arianne Buchan
C. Arianne Buchan
DADavid Allan
David Allan
The management of COVID-19 in hematopoietic cell transplant (HCT) recipients represents a special challenge given the variable states of immune dysregulation and altered vaccine efficacy in this population. A systematic search (Ovid Medline and Embase on 1 June 2021) was needed to better understand the presenting features, prognostic factors, and treatment options. Of 897 records, 29 studies were identified in our search. Most studies reporting on adults and pediatric recipients described signs and symptoms that were typical of COVID-19. Overall, the mortality rates were high, with 21% of adults and 6% of pediatric HCT recipients succumbing to COVID-19. The factors reported to be associated with increased mortality included age (HR = 1.21, 95% CI 1.03–1.43, p = 0.02), ICU admission (HR = 4.42, 95% CI 2.25–8.65, p < 0.001 and HR = 2.26, 95% CI 1.22–4.20, p = 0.01 for allogeneic and autologous HCT recipients), and low platelet count (OR = 21.37, 95% CI 1.71–267.11, p = 0.01). Performance status was associated with decreased mortality (HR = 0.83, 95% CI 0.74–0.93, p = 0.001). A broad range of treatments was described, although no controlled studies were identified. The risk of bias, using the Newcastle–Ottawa scale, was low. Patients undergoing HCT are at a high risk of severe morbidity and mortality associated with COVID-19. Controlled studies investigating potential treatments are required to determine the efficacy and safety in this population.

24 August 2017 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
HDHeidi Dutton
Heidi Dutton
MDMary-Anne Doyle
Mary-Anne Doyle
CBC. Arianne Buchan
C. Arianne Buchan
SMShuhiba Mohammad
Shuhiba Mohammad
KAKristi B. Adamo
Kristi B. Adamo
DFDean A. Fergusson
Dean A. Fergusson
The prevalence of obesity is increasing worldwide, and there is growing interest in better delineating the role of the human gut microbiome in this phenomenon. Obesity-specific gut microbiome features have been observed in both human and animal studies, and these variations appear to play a causative role in increasing body weight. There is evidence that antibiotics can modify the composition and diversity of the gut microbiome and that this may contribute to body weight changes. The primary objective of the proposed systematic review is to evaluate and synthesize the existing evidence evaluating the possible association between antibiotic use, weight gain, and obesity. A comprehensive search of the MEDLINE and EMBASE databases will be performed. Both randomized and non-randomized studies (excluding case reports) in neonates, children, adults, and pregnant women will be included. The exposure of interest is antibiotics of any type, duration, and route given for any indication. All included studies must have a comparator group. The primary outcomes are the development of overweight and obesity. Secondary outcomes are percent weight-change from baseline and change in body mass index or waist circumference. Additional secondary outcomes in pregnant women are gestational weight gain, postpartum weight retention, offspring birth weight, childhood weight, and obesity. Risk of bias of included trials will be performed. Two reviewers will screen and perform data extraction independently. This systematic review will summarize the existing evidence evaluating the association between antibiotic use, weight gain, and obesity and facilitate the identification of important gaps and uncertainties in the literature. PROSPERO CRD42017069177

1 March 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CBC. Arianne Buchan
C. Arianne Buchan
HLHeidi Oi-Yee Li
Heidi Oi-Yee Li
CHChristophe L. Herry
Christophe L. Herry
NSNathan Scales
Nathan Scales
PMPaul MacPherson
Paul MacPherson
ASAndrew J.E. Seely
Andrew J.E. Seely
Early warning of infection is critical to reduce risk of deterioration and mortality, especially in neutropenic patients following hematopoietic stem cell transplantation (HCT). Given that heart rate variability (HRV) is a sensitive and early marker for infection and serum inflammatory biomarkers can have high specificity for infection, we hypothesized their combination may be useful for accurate early warning of infection. Develop and evaluate a composite predictive model utilizing continuous HRV with daily serum biomarker measurements to provide risk stratification of future deterioration in HCT patients. 116 ambulatory outpatients about to undergo HCT consented to collection of prospective demographic, clinical (daily vital signs), HRV (continuous electrocardiogram (ECG) monitoring, laboratory (daily serum samples frozen -80°C) and infection outcome variables (defined as the time of escalation of antibiotics), all from 24 hours (h) pre-transplant until infection or 14 days post-transplant. Indications for antibiotic escalation were adjudicated as "true infection" or not by two blinded HCT clinicians. A composite time series of 8 HRV metrics was created for each patient and the probability of deterioration within the next 72h was estimated using logistic regression modelling of composite HRV and serum biomarkers using a rule-based Naïve-Bayes model, if the HRV-based probability exceeded a median threshold. 35(30%) patients withdrew within 90% incidence of subsequent infection within 72h), average risk (∼50%) and low risk (<10%), with an area under the receiver operating characteristic curve (AUC-ROC) of 0.87. We derived a predictive model using HRV and serum biomarker to predict being diagnosed with infection within 72h combined in patients at high risk of infection. As prophylactic predictive ECG monitoring and daily serum collection proved challenging for many patients, further refinement in measurement is necessary for further study.